Advertisement

Supportive Care in Cancer

, Volume 26, Issue 3, pp 751–758 | Cite as

Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study

  • Hélène Kolesnikov-GauthierEmail author
  • Nathalie Lemoine
  • Emmanuelle Tresch-Bruneel
  • Anaïs Olivier
  • Aurore Oudoux
  • Nicolas Penel
Original Article

Abstract

Purpose

The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting.

Methods

We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question “Do you think you obtained a benefit from treatment?” Success of treatment was defined by the combination of these four parameters.

Results

Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases.

Conclusion

153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.

Keywords

Samarium153 Bone metastases Pain palliative Radiometabolic therapy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Paes FM, Serafni AN (2010) Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Sem Nucl Med 40:89–104CrossRefGoogle Scholar
  2. 2.
    Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365PubMedGoogle Scholar
  3. 3.
    Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591CrossRefPubMedGoogle Scholar
  4. 4.
    Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–1581CrossRefPubMedGoogle Scholar
  5. 5.
    Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ (1999) Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylenediaminetetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 26:2–7CrossRefPubMedGoogle Scholar
  6. 6.
    Sartor O, Reid RH, Bushnell DL, Quick DP, Ell AJ (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637–643CrossRefPubMedGoogle Scholar
  7. 7.
    Correa-Gonzalez, Arteaga de Murphy C, Pichardo-Romero P, Pedraza-Lopez M, Moreno-Garcia C, Correa-Hernandez L (2014) 153Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res 45:301–308CrossRefPubMedGoogle Scholar
  8. 8.
    Tripathi M, Singhal T, Chandrasekhar N, Kumar P, Bal C, Jhulka PK, Bandopadhyaya G, Malhotra A (2006) Samarium-153 ethylediamine tretramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer 43:86–93CrossRefPubMedGoogle Scholar
  9. 9.
    Montesano T, Giacomobono S, Acqualagna G, Colandrea M, Di Nicola A, Travascio L, Giancamerla M, D'Apollo R, Toteda M, Ugolini F, Filesi M, Ronga G (2009) Our experience on pain palliation of bone metastases with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study. Clin Ter 160:193–199PubMedGoogle Scholar
  10. 10.
    Collins C, Eary JF, Dnaldson G, Vernon C, Busch NE, Petersdorf S (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34:1839–1844PubMedGoogle Scholar
  11. 11.
    Thapa P, Nikam D, Das T, Sonawane G, Agarwal JP, Basu S (2015) Clinical efficacy and safety comparison of 177Lu-EDTMP with 153Sm-SDTMP on an equidose basis in patients with painful skeletal metastases. J Nucl Med 56:1513–1519CrossRefPubMedGoogle Scholar
  12. 12.
    Heron DE, Brufsky A, Beriwal S, Kurman M (2008) Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol 19:1639–1643CrossRefPubMedGoogle Scholar
  13. 13.
    Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A (2009) Phase II trial of consolidation docetaxel and Samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27:2429–2435CrossRefPubMedGoogle Scholar
  14. 14.
    Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ (2009) Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 27:3319–3324CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Pettrili G, Maini CL (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79–86PubMedGoogle Scholar
  16. 16.
    Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopft DE, Hong C, Heller G, Scher HI, Larson SM, Morris MJ (2013) Repetitively dosed docetaxel and 153Samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer 119:3186–3194CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Hélène Kolesnikov-Gauthier
    • 1
    Email author
  • Nathalie Lemoine
    • 2
  • Emmanuelle Tresch-Bruneel
    • 3
  • Anaïs Olivier
    • 1
  • Aurore Oudoux
    • 1
  • Nicolas Penel
    • 2
    • 4
  1. 1.Department of Nuclear MedicineCentre Oscar LambretLille CedexFrance
  2. 2.Medical Oncology DepartmentOscar Lambret CenterLilleFrance
  3. 3.Methodology and Biostatistics UnitOscar Lambret CenterLilleFrance
  4. 4.Public Health Research Unit (EA2694: Epidemiology and Quality of Care)Lille University, Medical SchoolLilleFrance

Personalised recommendations